Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Journal: Therapeutic advances in medical oncology
Published: May 21, 2024
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 08, 2024
Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series.
Journal: Gynecologic oncology reports
Published: September 30, 2023
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 07, 2015
Apolipoprotein concentrations are elevated in malignant ovarian cyst fluids suggesting that lipoprotein metabolism is dysregulated in epithelial ovarian cancer.
Journal: Cancer investigation
Published: May 01, 2013
Ten-year relative survival for epithelial ovarian cancer.
Journal: Obstetrics and gynecology
Published: August 24, 2012
Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening.
Journal: Obstetrics and gynecology
Published: November 23, 2011
Showing 1-7 of 7
Last Updated: 09/26/2026